<DOC>
	<DOCNO>NCT00004832</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety effectiveness 3,4-diaminopyridine ( DAP ) treatment patient Lambert-Eaton myasthenic syndrome ( LEMS ) . II . Determine side-effects benefit associate DAP .</brief_summary>
	<brief_title>Randomized Study 3,4-Diaminopyridine Lambert-Eaton Myasthenic Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control study . Patients randomized receive 3,4-diaminopyridine ( DAP ) placebo orally 3 time daily 5 day , treatment discontinue patient observe least 24 hour . At end blind study , patient may elect take open label DAP orally 3 time daily 6 month ; monitor clinical effect side effect least 6 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics LambertEaton myasthenic syndrome ( LEMS ) base weakness predominates proximal limb muscle electromyography ( EMG ) find small amplitude muscle response nerve stimulation , decrease nerve stimulation 5 Hz increase least 2fold maximum voluntary contraction muscle 1020 second Quantified Myasthenia Gravis ( QMG ) clinical score least 5 Prior/Concurrent Therapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : Patients receive immunosuppressant must dose medication least 3 month prior study entry Radiotherapy : No concurrent radiotherapy Surgery : No concurrent surgery Other : Patients receive cholinesterase inhibitor must discontinue medication study entry possible , else dose medication least 1 month prior study entry Patient Characteristics Hematopoietic : No significant hematologic disease Hepatic : No significant hepatic disease Renal : No significant renal disease Cardiovascular : No cardiac arrhythmia significant cardiac disease Neurologic : No seizure disorder Other : Not pregnant Negative pregnancy test require fertile woman Effective contraception require fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>Lambert-Eaton myasthenic syndrome</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>